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Abstract
Interferon induced with helicase C domain 1 (IFIH1) senses and initiates antiviral activity against enteroviruses. Genetic
variants of IFIH1, one common and four rare SNPs have been associated with lower risk for type 1 diabetes. Our aim was to
test whether these type 1 diabetes-associated IFIH1 polymorphisms are associated with the occurrence of enterovirus
infection in the gut of healthy children, or influence the lack of association between gut enterovirus infection and islet
autoimmunity. After testing of 46,939 Norwegian newborns, 421 children carrying the high risk genotype for type 1
diabetes (HLA-DR4-DQ8/DR3-DQ2) as well as 375 children without this genotype were included for monthly fecal collections
from 3 to 35 months of age, and genotyped for the IFIH1 polymorphisms. A total of 7,793 fecal samples were tested for
presence of enterovirus RNA using real time reverse transcriptase PCR. We found no association with frequency of
enterovirus in the gut for the common IFIH1 polymorphism rs1990760, or either of the rare variants of rs35744605,
rs35667974, rs35337543, while the enterovirus prevalence marginally differed in samples from the 8 carriers of a rare allele
of rs35732034 (26.1%, 18/69 samples) as compared to wild-type homozygotes (12.4%, 955/7724 samples); odds ratio 2.5,
p=0.06. The association was stronger when infections were restricted to those with high viral loads (odds ratio 3.3, 95% CI
1.3–8.4, p=0.01). The lack of association between enterovirus frequency and islet autoimmunity reported in our previous
study was not materially influenced by the IFIH1 SNPs. We conclude that the type 1 diabetes-associated IFIH1
polymorphisms have no, or only minor influence on the occurrence, quantity or duration of enterovirus infection in the gut.
Its effect on the risk of diabetes is likely to lie elsewhere in the pathogenic process than in the modification of gut infection.
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Introduction
Enteroviruses (family Picornaviridae) cause mostly inapparent or
subclinical infections; acute disease may range from minor illness
to paralytic disease [1]. Enteroviruses are thought to cross the
intestinal epithelium via M-cells [2] and to replicate primarily in
the lymphoid tissues of the gut [3,4].
IFIH1 (interferon induced with helicase C domain 1), also
known as MDA5 (melanoma differentiation associated gene 5),
encodes a cytoplasmic sensor that recognizes certain types of
double stranded RNA (dsRNA) molecules, which are commonly
produced during the replication of some RNA viruses. Signaling
via IFIH1 triggers activation of NF-kB and interferon regulatory
pathways, and induces antiviral interferon responses [5]. IFIH1 is
triggered by picornaviruses [6,7], and two recent publications have
found in vivo effects of IFIH1 in mda5 knockout mice infected with
coxsackievirus [8,9].
Enteroviruses have been considered as possible environmental
triggers or accelerators of islet autoimmunity leading to type 1
diabetes [10–12]. The relation seems complex, with partially
conflicting results [13]; the research has been going on for more
than 30 years now. This hypothesis was greatly sparked when a
genome-wide association study of type 1 diabetes identified a
significant relation with a common polymorphism in IFIH1 [14].
This association is now convincingly established (odds ratio around
0.85 for the minor allele) [15–19].
Recently, deep sequencing of exons and splice sites in the
IFIH1 gene revealed that lower risk of type 1 diabetes is also
associated with two rare variants with a presumed loss of
function (nonsynonymous SNPs rs35744605 (E627X) and
rs35667974 (I923V)), and with two noncoding variants affecting
conserved splice sites (rs35337543 (1641+1G.C)) and
rs35732034 (2807+1G.A)), odds ratios of about 0.5–0.7 [20].
The mechanisms relating IFIH1 polymorphisms to type 1
diabetes, and if enterovirus is involved here, remains unclear
and paradoxical. Presumably, variants associated with reduced
IFIH1 function would confer the host with a mild antiviral
response to enterovirus infection. If so, this would influence the
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27781observed association between enterovirus frequency and type 1
diabetes in the population, and failure to account for IFIH1
SNPs in population studies could be hypothesized to ‘‘conceal’’
relations between enterovirus and islet autoimmunity or type 1
diabetes.
The primary aim of the present study was to assess in healthy
children whether the IFIH1 polymorphisms associated with type 1
diabetes can predict frequency, viral load, or duration of gut
infections with enterovirus. We further aimed to test whether our
previously reported lack of association between enterovirus and
islet autoimmunity was modified by taking these IFIH1 polymor-
phisms into account.
Methods
Subjects and study design
The participants were identified and recruited in the MIDIA-
study that during 2001–2007 screened 46,939 newborns from the
Norwegian general population for the HLA genotype DRB1*04:01-
DQA1*03-DQB1*03:02/DRB1*03-DQA1*05-DQB1*02 (DR4-DQ8/
DR3-DQ2) which confers high risk for type 1 diabetes [21]. The
present analysis is based on nearly 8,000 fecal samples from 421
children with the HLA DR4-DQ8/DR3-DQ2 genotype and 375
children without this genotype, as described in detail in Figure 1.
In a separate analysis, we studied whether the IFIH1
polymorphisms modified the risk of type 1 diabetes-related islet
autoimmunity among children with the HLA-DR4-DQ8/DR3-DQ2
genotype (Figure 1). Blood samples from these children drawn at
ages 3, 6, 9 and 12 months, and annually thereafter were tested for
islet autoantibodies (to insulin, glutamic acid decarboxylase, or the
protein phosphatase IA2) using radiobinding assays as previously
described [21]. The endpoint of islet autoimmunity was defined as
repeated positivity for two or three islet autoantibodies. Controls
without islet autoimmunity were matched for the HLA DR4-DQ8/
DR3-DQ2 genotype, date of birth, length of follow-up and county
of residence [13] (Figure 1).
Ethics statement
Written informed consent was provided by participating
families. The study was approved by The Regional Committee
for Medical Research Ethics (IRB name: ‘‘Regional Med Resch
Ethics Comm South IRB #2 - South-East A’’, IRB00001871) and
the Norwegian Data Inspectorate.
Detection of enterovirus RNA in fecal samples
Fecal samples were tested for enterovirus as described earlier
[13]. Nucleic acids were co-purified from supernatants of
centrifuged feces, and tested for human enterovirus RNA using
an internally controlled quantitative reverse transcriptase real-time
PCR with primers and probes described in [22]. The median
number of fecal samples tested per child was 9 (range 1–36) and
the median age at last fecal sample was 12.1 months (range 2.8–
37.5).
Figure 1. Flow chart illustrating the details of inclusion of children and samples in the current analysis. *HLA-DRB1*04:01-DQA1*03-
DQB1*03:02/DRB1*03-DQA1*05-DQB1*02 (DR4-DQ8/DR3-DQ2), conferring high risk for type 1 diabetes. **For each child identified with the high-risk
genotype, about 1–4 children without the high risk genotype were enrolled from the same county.
doi:10.1371/journal.pone.0027781.g001
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Subjects were genotyped for one common IFIH1 SNP
(rs1990760, A946T), and four rare SNPs rs35744605 (E627X),
rs35667974 (I923V), rs35732034 (intron 14, 2807+1) and
rs35337543 (intron 18, 1641+1). SNP genotyping of rare variant
SNPs was performed with the MassARRAY system using iPLEX
chemistry (Sequenom, San Diego, CA). The common SNP
rs1990760 was genotyped using TaqMan technology with
predesigned primer-probe mixes (Applied Biosystems, Foster City,
CA, USA). Among children with at least one fecal sample tested
for enterovirus (n=808), genotyping with the MassARRAY
system failed in 5–8 DNA samples (,0.1%), and with TaqMan
only two samples failed. Duplicate genotyping was performed in
5% randomly chosen samples, with 100% concordance.
Statistical analysis
The final sample for analysis included 796 children and their
7,793 fecal samples (Figure 1). There was no evidence for
deviation from Hardy–Weinberg equilibrium (x
2 test) in either
of the polymorphisms. Haploview 4.2 was used to assess linkage
disequilibria between the alleles of the typed SNPs. Association
analyses were performed using logistic regression models with
enterovirus infection (yes or no) as the response, individual SNP
genotypes as predictors, and a random intercept to account for
potential intra-individual correlation (clustering) of infections
(xtmelogit in STATA11, StataCorp).
Apart from taking enterovirus positivity as an outcome, in
further sensitivity analysis we restricted infections to those with
above median quantity of enterovirus RNA among positive
samples (defined as high viral load: 10,000 or more virus copies/
ml), or to the first enterovirus RNA positive samples among series
of two or more consecutively positive samples. Prolonged infection
episodes with at least two consecutively positive samples were
assessed by excluding other positive samples.
Furthermore, cases of islet autoimmunity and matched controls
from our previous publication [13] were compared with respect to
enterovirus frequency, and the influence of the IFIH1 SNPs
evaluated. This was modeled similarly as for the IFIH1 SNP-
enterovirus relation, but with autoimmunity status as a covariate
and an additional random intercept to specify matched set (three
level random intercept model [23]). These analyses were adjusted
for, and stratified by the common variants of IFIH1 SNP
rs1990760. The impact of the four rare variant IFIH1 SNPs on
the relation between enterovirus infections and islet autoimmunity
could only be evaluated by exclusion of subjects with rare variant
of either SNP. Matched case-control data at the individual level
were done using conditional logistic regression, with additional
adjustment for cumulative number of enterovirus infections before
seroconversion for islet autoantibodies for cases, and the
corresponding time for matched controls.
In our pre-study power considerations, we used parameters
from our previously published pilot studies [22,24] and the
literature [14,20], and estimated that we could detect odds ratios
of at least 1.3 of the common IFIH1 A946T variant, and odds
ratios at about 2–4 for the various rare variants with approxi-
mately 80% power.
Results
Cohort study of IFIH1 SNPs and enterovirus frequency
The frequencies of enterovirus in fecal samples by genotypes of
the five SNPs are shown in Table 1. While neither the common
polymorphism rs1990760, nor the rare rs35744605, rs35337543,
rs35667974 of IFIH1 showed any association with presence,
Table 1. Prevalence (%) of enterovirus RNA in fecal samples and frequency of positive samples with a high viral load according to
IFIH1 genotypes.
Enterovirus prevalence Samples of high viral load*
N=7,793 (796 children) N=7,309 (793 children)
IFIH1 SNPs{{ Genotypes Frequency % OR Frequency % OR
(n children) (n samples/n total) (95% CI) P-value (n samples/n total) (95% CI) P-value
rs35337543 GG (788) 12.5 (963/7,677) 1.0 (ref) 6.3 (483/7,676) 1.0 (ref)
CG (8) 8.6 (10/116) 0.78 (0.30–2.04) 0.61 5.2 (6/116) 0.89 (0.31–2.51) 0.82
rs35744605 GG (786) 12.5 (964/7,700) 1.0 (ref) 6.3 (483/7,699) 1.0 (ref)
GT (10) 9.7 (9/93) 0.90 (0.35–2.37) 0.84 6.5 (6/93) 1.19 (0.43–3.30) 0.74
rs35667974 AA (752) 12.6 (926/7,376) 1.0 (ref) 6.4 (468/7,375) 1.0 (ref)
AG (44) 11.3 (47/417) 0.86 (0.55–1.36) 0.53 5.0 (21/417) 0.78 (0.46–1.33) 0.36
rs35732034 GG (788) 12.4 (955/7,724) 1.0 (ref) 6.2 (477/7,723) 1.0 (ref)
GA (8) 26.1 (18/69) 2.47 (0.97–6.30) 0.06 17.4 (12/69) 3.35 (1.34–8.38) 0.01
rs1990760 CC (135) 10.6 (130/1,229) 1.0 (ref) 0.721 5.5 (67/1,128) 1.0 (ref) 0.911
CT (386) 13.1 (493/3,756) 1.22 (0.91–1.63) 6.8 (255/3,756) 1.25 (0.89–1.74)
TT (275) 12.5 (350/2,808) 1.12 (0.82–1.52) 6.0 (167/2,808) 1.10 (0.77–1.56)
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
*Excluding enterovirus positive samples with a low-intermediate virus quantity (below 10,000 virus copies/ml enterovirus RNA).
{Location of IFIH1 SNPs: rs35337543 (intron 18, 1641+1, G.C), rs35744605 (exon 10, E627X, G.T), rs35667974 (exon 14, I923V, A.G), rs35732034 (intron 14, 2807+1,
G.A), rs1990760 (exon 14, A946T, T.C).
{Reports of functional effects associated with IFIH1 SNPs: rs35337543 and rs35732034 influences on a putative splice site, rs35744605 is associated with loss of function
(ATPase activity, dsRNA binding, truncation of protein), rs35667974 is associated with loss of function (ATPase activity, dsRNA binding), and rs1990760 is not associated
with loss of function (reviewed in [29]).
1Test for trend (1 d.f.).
doi:10.1371/journal.pone.0027781.t001
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Table S1), we observed a statistically non-significant tendency
towards association for rs35732034 (Table 1). Here the enterovirus
prevalence was 26.1% (18/69 samples) among the 8 children
carrying the GA genotype, and 12.4% (955/7724 samples) among
children with the wild type variant (OR=2.5, P=0.06).
This suggestive association was strengthened when the analysis
was restricted to infections with high viral loads (OR=3.4,
P=0.01, Table 1). The association with high viral load remained
significant after adjustment for age, calendar year and season of
sample collection (p-values 0.01 to 0.025 and ORs 3.35 to 2.97,
data not shown). The association with this rare variant of
rs35732034 was also consistent (but not statistically significant)
when restricting the analysis to infectious episodes (OR=1.9,
P=0.06) or to prolonged infections (OR=2.5, P=0.09) (Table
S1). As there were no correlations between the tested SNPs (all
r
2,0.04), the above association is unlikely to be explained by
linkage disequilibrium to other known diabetes-associated variants.
The association of each IFIH1 SNP with enterovirus was similar
among children with and without the type 1 diabetes-associated
HLA DR4-DQ8/DR3-DQ2 high-risk genotype, respectively (data
not shown).
Nested case control study of islet autoimmunity
We next assessed whether taking the IFIH1 polymorphisms into
account would modify our previously published observation of no
association between enterovirus frequency and islet autoimmunity
[13]. Adjusting for rs1990760 and excluding the 1 case and 6
controls with a rare variant of rs35744605, rs35667974,
rs35732034, or rs35337543 did not influence the results materially
(Table 2). There was no significant heterogeneity in the association
between enterovirus frequency and islet autoimmunity that would
depend on the common IFIH1 rs1990760 (Table 2). Finally,
rs1990760 was not significantly associated with persistent
autoimmunity before or after adjusting for the cumulative number
of enterovirus infections within a child prior to the development of
persistent autoimmunity (Table 2).
Discussion
We found a potential association between a presumed loss of
function variant in the IFIH1 gene, the rare SNP rs35732034, and
a higher frequency of high quantity fecal shedding of enterovirus
in infants. Our most important finding however, was the lack or
minor influence of the IFIH1 gene variants on the occurrence,
quantity or duration of enterovirus gut infections of healthy
infants. Furthermore, taking all these five IFIH1 polymorphisms
into account did not influence our previously reported lack of
association between enterovirus frequency and risk of islet
autoimmunity in children with the type 1 diabetes susceptibility
HLA-DR4-DQ8/DR3-DQ2 genotype.
Strengths and limitations
To our knowledge, this is the first study investigating the
potential impact of diabetes-associated IFIH1 polymorphisms on
the frequency and viral load of enterovirus in the gut of healthy
infants. Strengths of the present study are the very large number of
samples analysed, the population based, longitudinal design, and
the rather frequent interval of fecal sample collection. As
enteroviruses are thought to replicate primarily in the intestine,
and the virus is shed for weeks after an infection, our study is likely
to cover the majority of enterovirus infections. We did not study
systemic spread of enterovirus, as blood samples would have to be
extremely frequent in order to systematically cover most infections:
enterovirus is usually present in the blood for a much shorter
period than in the gut [1].
Table 2. Frequency of enterovirus RNA in faecal samples prior to islet autoimmunity and matched controls and influence of IFIH1
polymorphisms.
Cases* Controls* OR (95% CI){ OR (95% CI){
(n=25 subjects) (n=50 subjects) Unadjusted Adjusted
EV infection and later development of islet autoimmunity:
EV2 282 555 1.00 (reference) 1.00 (reference)
EV+ 42 (13.0%) 93 (14.4%) 0.95 (0.58–1.55), P=0.83 0.99 (0.62–1.60){
The association of IFIH1 rs1990760 polymorphisms with islet autoimmunity:
rs1990760 Ala2 9 (36.0%) 20 (40.0%) 1.00 (reference) 1.00 (reference)
rs1990760 Ala+ 16 (64.0%) 30 (60.0%) 1.18 (0.44–3.14); P=0.74 OR=1.2 (0.44–3.26)1
EV infection and later development of islet autoimmunity, stratified by IFIH1 rs1990760:
EV2, rs199076, Ala2 181 (86.2%) 300 (86.0%) 1.00 (reference)
EV+, rs199076, Ala2 29 (13.8%) 49 (14.0%) 0.77 (0.34–1.77)
EV2, rs199076, Ala+ 101 (88.6%) 255 (85.3%) 1.00 (reference)
EV+, rs199076, Ala+ 13 (11.4%) 44 (14.7%) 1.04 (0.50–2.15) P(interaction)=0.74I
EV, enterovirus; OR, odds ratio; CI, confidence interval.
*Cases defined as repeated positivity in consecutive blood samples for two or three islet autoantibodies (anti-insulin, anti-GAD, anti-IA2). Controls matched by high risk
HLA genotype, date of birth, time of follow-up and county of residence. See reference [13] for more details.
{Estimated from a three level random intercept logistic regression model with enterovirus positivity as dependent variable and case/control status and IFIH1 SNPs as
independent variables. Nested random effects were specified for individuals (samples within individuals) and for matched set (individuals within matched sets of a case
and 1–2 controls).
{Enterovirus adjusted for IFIH1 common variant rs1990760 and vice versa. Rare variants could not be adjusted for because of zero observations in one of the comparing
groups. Instead subjects/samples with rare variants of these SNPs were excluded from the analysis (1 case, 6 controls; in total 184 samples).
1Adjusted for the cumulative number of enterovirus infections within a child until persistent autoimmunity develops.
ITesting whether the model stratified for Thr/Thr is significantly different from the model stratified for carriers of at least one Ala allele.
doi:10.1371/journal.pone.0027781.t002
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variants to enterovirus RNA in humans, one that investigated the
common rs1990760 but which was severely underpowered for
genetic association analysis [25] and one relatively large study of
young adult patients with established type 1 diabetes (and non-
diabetic controls) that investigated two rare type 1 diabetes IFIH1
variants (rs35744605 and rs35667974) [26]. Both of these studies
assayed samples from a single time point from each subject, and
may consequently have missed important information on the
temporal dimension of the infection. Nevertheless, the rare variant
of rs35667974 was slightly more frequent among patients positive
for enterovirus RNA in blood compared to enterovirus negative
patients [26]. These studies [25,26], like ours, lack information on
enterovirus serotype (genotype). The high number of specific types
of enterovirus would require a prohibitively large number of
samples for reasonable statistical power for individual serotypes.
While we had good power to detect potential associations of small
to moderate magnitude (OR,2.0) of the common IFIH1 SNP our
data suggest that the per allele odds ratio is highly unlikely to be
greater than about 1.2 (upper 95% CI for per allele trend OR). We
cannot exclude weak to moderate effects of the rare variants
because of limited power, but the possible existence of such weak
effects of rare IFIH1 variants on enterovirus infections would have
limited population impact on the epidemiology of enterovirus
infections, if any at all.
Potential explanations of our main findings
If the suggestive association between the rare A variant of
rs35732034 and frequency of high quantity enteroviral infections
is true, this indicates a dominant or dose-dependent effect of the
predicted interference with splicing of the intron [20]. We can only
speculate on the potential mechanisms explaining this phenome-
non, while the other established type 1 diabetes associated
polymorphisms did not predict enterovirus infections. Predictions
based on sequence analysis of the rare variants [20], supported by
some experimental functional studies [26–28], suggest that the
rare variants associated with lower risk of type 1 diabetes are loss
of function variants (functional studies are reviewed in [29]). Most
such functional in vitro studies are limited to one or a few aspects
of function in one or a few cell types taken out of their in vivo
context, and perhaps with limited or uncertain sensitivity. We
must keep in mind that the endpoint observed in the current study,
fecal shedding of enteroviral RNA, is the likely the result of a very
complex interaction between the human host and the viral agent
and probably activation of a number of signaling pathways in
multiple cell types. While there is no obvious reason to suspect that
the functional consequences of the rare variant of rs35732034
should be more severe than that of the other three rare variant
SNPs studied, our results indicate that one normal allele is
sufficient for eliciting a physiological normal antiviral host immune
control of enterovirus infections in the gut of otherwise healthy
infants, at least for the SNPs not associated with enterovirus
frequency. One reason for lack of association could be the
involvement of complementary innate antiviral pathways, such as
those involving the Toll-like receptors (reviewed in [30]),
explaining why IFIH1 was not essential for IFN-production after
an enterovirus infection in mda5 knockout mice [8]. Another
potential explanation could be one of the pathogen survival
strategies of host immune evasion involving degradation of host
IFIH1 signaling molecules [31]. The two groups who have
experimentally infected mda5 knockout mice with coxsackievirus
have produced partially conflicting results, but one group showed
significantly decreased production of type I IFN, but this was not
correlated with increased virus titers [9]. The other group showed
that type I IFN levels were not affected, but viruses titers were
markedly increased transiently [8].
Enterovirus infections and type 1 diabetes related islet
autoimmunity
The evidence for the involvement of the enterovirus genus in type
1 diabetes pathogenesis seem likely, yet the limited numbers of
available longitudinal studies of islet autoimmunity where
enteroviral RNA have been tested as a risk factor have been
inconsistent between populations and sources of the sample
[13,32–38]. The evidence seems to be limited to detection in
blood or its fractions and predominantly studies done in Finland
where serum enterovirus RNA [38] or combined with increases in
enterovirus antibodies have been used as indicators of infection
[34–36]. This is in contrast to studies from other countries (USA
and Germany) showing no association [32,33]. Neither, studies
assessing enterovirus RNA in fecal specimens show any association
with islet autoimmunity [13,32,37].
The IFIH1 alleles that had been previously associated with
reduced type 1 diabetes risk were predicted to be loss of function
variants, and may thus confer increased risk for enterovirus
infection. We therefore reasoned that our previously published
lack of association between enterovirus RNA and islet autoimmu-
nity [13] could be influenced by adjustment for the IFIH1 SNPs.
However, adjusting for IFIH1 (rs1990760) and the exclusion of
children with rare IFIH1 alleles did not influence the lack of
association. A prospective cohort study recently reported lack of
association with islet autoantibody development for genotypes of
the IFIH1 SNP rs2111485, a SNP in close proximity and in strong
linkage disequilibrium with rs1990760. While this may partially be
explained by limited statistical power, their study showed an
association with faster progression from autoimmunity to type 1
diabetes [39]. This may hint towards a potential role in a different
immunological context, but which would be very demanding to
study in humans.
In conclusion, despite the predictions that rare IFIH1 variants
previously associated with type 1 diabetes are loss of function
variants, and experimental data showing an important role of
IFIH1 in antiviral immunity to enteroviruses, out data suggests
that these variants have no or just minor impact on the frequency
and duration of gut infection with enterovirus in healthy infants.
Its effect on the risk of diabetes is likely to lie elsewhere in the
pathogenic process than in the modification of gut infection
frequency.
Supporting Information
Table S1 The effect of IFIH1 genotypes on different
measures of enterovirus infection in longitudinal fecal
samples.
(DOC)
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